Form 4 for DMRA Damora Therapeutics, Inc.
Accepted 2026-02-12 00:00:00 ET · period of report 2026-02-09 · accession 0001193125-26-047535 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2026-02-12 | 2026-02-09 | DMRA | Fairmount Healthcare Fund II L.P. | 10% | M - OptEx | $0.00 | +8.71M | 2.90M | New | $0 |
| DMI | 2026-02-12 | 2026-02-09 | DMRA | Fairmount Healthcare Fund II L.P. | 10% | M - OptEx | $0.00 | -8,713 | 574 | -94% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-09 | M | A | 5,809,000 | $0.00 | 5,809,000 | I By Fairmount Healthcare Fund II L.P. | — | — | (F3) Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fund II and Co-Invest. Peter Harwin and Tomas Kiselak are the managers of Fairmount. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| 2 | Common | Common Stock | 2026-02-09 | M | A | 2,904,000 | $0.00 | 2,904,000 | I By Fairmount Healthcare Co-Invest V L.P. | — | — | (F3) Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fund II and Co-Invest. Peter Harwin and Tomas Kiselak are the managers of Fairmount. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| 3 | Derivative | Series C Preferred Stock | 2026-02-09 | M | D | 5,809 | $0.00 | 1,148 | I By Fairmount Healthcare Fund II L.P. | — · — to — | 5,809,000 Common Stock | (F3) Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fund II and Co-Invest. Peter Harwin and Tomas Kiselak are the managers of Fairmount. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F4) Following receipt of the Requisite Stockholder Approval, each share of Series C Preferred Stock automatically converted into 1,000 shares of Common Stock, subject to certain beneficial ownership limitations. The Series C Preferred Stock has no expiration date. Fairmount may not convert such shares if Fairmount, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion. |
| 4 | Derivative | Series C Preferred Stock | 2026-02-09 | M | D | 2,904 | $0.00 | 574 | I By Fairmount Healthcare Co-Invest V L.P. | — · — to — | 2,904,000 Common Stock | (F3) Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fund II and Co-Invest. Peter Harwin and Tomas Kiselak are the managers of Fairmount. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F4) Following receipt of the Requisite Stockholder Approval, each share of Series C Preferred Stock automatically converted into 1,000 shares of Common Stock, subject to certain beneficial ownership limitations. The Series C Preferred Stock has no expiration date. Fairmount may not convert such shares if Fairmount, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion. |